CIN is a cervical condition caused by a sexually transmitted virus known as the Individual Papilloma Virus that can result in invasive cervical cancer, if not diagnosed and still left untreated properly. Currently, the typical treatment for late stage CIN is medical procedures to preclude invasive cancer, and there are approximately 250, 000 instances of CIN treated in this manner in the US annually. Recent fresh vaccines can prevent occurrence of CIN if administered before HPV is certainly contracted, but usually do not treat the condition itself. Related StoriesMylan announces U.S.Cohen, M.D., Werner Hacke, M.D., Ph.D., Olav Jansen, M.D., Ph.D., Tudor G. Jovin, M.D., Heinrich P. Mattle, M.D., Raul G. Nogueira, M.D., Adnan H. Siddiqui, M.D., Ph.D., Dileep R. Yavagal, M.D., Blaise W. Baxter, M.D., Thomas G. Devlin, M.D., Ph.D., Demetrius K. Lopes, M.D., Vivek K. Reddy, M.D., Richard du Mesnil de Rochemont, M.D., Oliver C. Singer, M.D., and Reza Jahan, M.D. For the SWIFT Primary Investigators: Stent-Retriever Thrombectomy after Intravenous t-PA vs. T-PA Alone in Stroke Intravenous tissue plasminogen activator administered within 4.5 hours following the onset of acute ischemic stroke improves outcomes.1-3 However, intravenous t-PA has multiple constraints, including unresponsiveness of large thrombi to fast enzymatic digestion, a narrow time window for administration, and the risk of systemic and cerebral hemorrhage.